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Abstract
Background/Aims: Genetic cell ablation using the human 
diphtheria toxin receptor (hDTR) is a new strategy used for 
analysing cellular function. Diphtheria toxin (DT) is a cyto-
toxic protein that leaves mouse cells relatively unaffected, 
but upon binding to hDTR it ultimately leads to cell death. 
We used a podocyte-specific hDTR expressing (Pod-DTR) 
mouse to assess the anti-permeability and cyto-protective 
effects of the splice isoform vascular endothelial growth fac-
tor (VEGF-A165b). Methods: The Pod-DTR mouse was crossed 
with a mouse that over-expressed VEGF-A165b specifically in 
the podocytes (Neph-VEGF-A165b). Wild type (WT), Pod-DTR, 
Neph-VEGF-A165b and Pod-DTR X Neph-VEGF-A165b mice 
were treated with several doses of DT (1, 5, 100, and 1,000 
ng/g bodyweight). Urine was collected and the glomerular 
water permeability (LpA/Vi) was measured ex vivo after 14 
days. Structural analysis and podocyte marker expression 
were also assessed. Results: Pod-DTR mice developed an in-
creased glomerular LpA/Vi 14 days after administration of DT 
(all doses), which was prevented when the mice over-ex-
pressed VEGF-A165b. No major structural abnormalities, 
podocyte ablation or albuminuria was observed in Pod-DTR 
mice, indicating this to be a mild model of podocyte disease. 
However, a change in expression and localisation of nephrin 
within the podocytes was observed, indicating disruption of 
the slit diaphragm in the Pod-DTR mice. This was prevented 
in the Pod-DTR X Neph-VEGF-A165b mice. Conclusion: Al-
though only a mild model of podocyte injury, over-expres-
sion of the anti-permeability VEGF-A165b isoform in the 
podocytes of Pod-DTR mice had a protective effect. There-
fore, this study further highlights the therapeutic potential 
of VEGF-A165b in glomerular disease.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Podocytes, glomerular endothelial cells (GEnCs) and 
mesangial cells function together to form and maintain 
the glomerular filtration barrier (GFB), which serves to 
filter water and small solutes from the blood into Bow-
man’s space while restricting the passage of large nega-
This article is licensed under the Creative Commons Attribution 4.0 
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tively charged plasma proteins, such as albumin [1]. In-
jury to any of these cells types can result in renal dysfunc-
tion. Podocyte damage is well documented to play a key 
role in glomerular pathologies; rearrangement of the pro-
teins that maintain the slit diaphragm can result in retrac-
tion/effacement of the podocyte foot processes, ultimate-
ly causing proteinuria [2]. Podocyte-targeted glomerular 
injury is problematic as podocytes lack the ability to pro-
liferate in response to neighbouring cell loss.
Genetic cell ablation using the human diphtheria tox-
in receptor (hDTR) is a relatively new strategy for analys-
ing cellular function: the use of a cytotoxic gene under the 
control of a cell/tissue specific promoter expressed in 
transgenic mice [3]. Diphtheria toxin (DT) is a cytotoxic 
protein that is secreted by the bacterium Corynebacteri-
um diphtheriae. Upon binding of the larger B subunit of 
DT to the hDTR, on the cell surface, the toxin is inter-
nalised within acidic endosomes. The acidic environment 
allows the smaller A subunit to dissociate and translocate 
to the cytosol where it becomes enzymatically active and 
ADP-ribosylates elongation factor-1. This ultimately in-
activates protein synthesis and results in cell death [4].
While most other transgenic models of podocyte in-
jury cause rapid and irreversible destruction of podocytes 
(e.g., the Thy1.1 model; anti-Thy1.1 is injected in to mice 
expressing ectopic Thy1.1 in the podocytes) [5], the 
hDTR system allows ablation of podocytes in vivo in a 
dose-dependent manner [6, 7]. Murine cells are approxi-
mately 1,000-fold less susceptible to DT than human cells 
due to an alternative region of amino acids in the extra-
cellular domain of murine DTR [4]. Wild-type (WT) 
mice receiving a single dose of 50 ng/g bodyweight (bw) 
DT have been reported to have no adverse effects [4]. 
However, more recent evidence states that an adverse ef-
fect to DT in WT mice may be strain dependent, as cer-
tain strains developed transient albuminuria in response 
to multiple doses of DT [8].
Murine models that express hDTR on the podocytes 
have previously been used to study glomerular disease in 
rats [7] and mice [6]. Furthermore, a mouse model that 
expressed DT within the podocytes has also been de-
scribed [9]. All 3 models provide strong evidence for 
podocyte depletion resulting in glomerulosclerosis and 
proteinuria in a dose-dependent manner. In our study, 
we used a mouse model that expressed podocyte-specific 
hDTR using a fragment of the nephrin promoter. Upon 
intraperitoneal injection of DT, mice have been reported 
to develop proteinuria and glomerulosclerosis [10]. 
Vascular endothelial growth factor A (VEGF-A) has 
been implicated in several types of kidney pathology, in-
cluding chronic renal failure [11, 12]. Alternative splicing 
of exon 8 of the VEGF-A gene gives rise to 2 functionally 
different isoform families – the pro-angiogenic VEGF-
Axxx family (main renal isoform: VEGF-A165) and the an-
ti-angiogenic VEGF-Axxxb family (main renal isoform: 
VEGF-A165b) [1]. VEGF-A165b has been suggested to 
comprise around 45% of the total VEGF-A protein in the 
human adult renal cortex [13]. This could explain the 
VEGF-A paradox in the kidney; a vast amount of VEGF-
A is expressed by the podocytes, signalling to VEGFR-2 
on the GEnCs; however, endothelial cell proliferation in 
the mature kidney is low. VEGF-A165b reduces GEnC 
permeability, inhibits cell migration and is cyto-protec-
tive to podocytes and GEnCs in culture, as well as in 
mouse models of diabetic nephropathy [13–15]. Further-
more, VEGF-A165b significantly reduces the phosphory-
lation of VEGFR-2 in HUVECs, compared to VEGF-A165 
[16], explaining its anti-angiogenic and anti-permeability 
properties. The Neph-VEGF-A165b mouse over-express-
es human VEGF-A165b under a nephrin promoter in a 
constitutive manner [17]. While over-expression of the 
pro-angiogenic isoform of VEGF-A (VEGF-A164) in 
mouse podocytes causes a glomerular disease phenotype 
[18, 19], the Neph-VEGF-A165b mice are viable through 
adulthood and present only with a phenotype of reduced 
glomerular water permeability likely to be due to reduced 
endothelial fenestral density [17].
This study aimed to determine the cyto-protective 
properties of VEGF-A165b over-expression in an estab-
lished model of podocyte injury. A double transgenic 
mouse model was generated, which expressed both hDTR 
and human VEGF-A165b in the podocytes. We propose 
that podocyte-expressed VEGF-A165b could prevent dis-
ruption of the GFB in the Pod-DTR model, and therefore 
protect normal renal function.
Methods
Animals
All experiments were conducted in accordance with UK legis-
lation and were approved by the University of Bristol research Eth-
ics Committee. All experiments and procedures were approved by 
the UK Home office in accordance with the Animals (Scientific 
Procedures) Act 1986, and the Guide for the Care and Use of Lab-
oratory Animals was followed. 
The Pod-DTR mice were a gift from Neil Turner, University 
of Edinburgh, UK. The hDTR is expressed under a fragment of 
the nephrin promoter, resulting in podocyte-specific expres-
sion. The Neph-VEGF-A165b mice were generated and bred in-
house [17]. Human VEGF-A165b is expressed under a nephrin 
promoter.
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The breeding strategy involved crossing Pod-DTR+/– mice with 
Neph-VEGF-A165b+/– mice, both on a c57BL/6 background, to 
generate litters with the 4 experimental groups required: wild-type 
(WT), Pod-DTR+/–, Neph-VEGF-A165b+/–, and Pod-DTR+/– X 
Neph-VEGF-A165b+/– mice. Both transgenes were kept heterozy-
gous throughout and were identified by PCR analysis of genomic 
DNA using the following primer pairs: Pod-DTR; 5′, 5′-GGTG 
GTGCTGAAGCTCTTTC-3′; 3′, 5′-GCTTGTGGCTTGGAGGA 
TAA-3′. Neph-VEGF-A165b; 5′, 5′-TCAGCGCAGCTACTGCC 
ATC-3′; 3′, 5′-GTGCTGGCCTTGGTGAGGTT-3′. A 218-bp 
fragment was amplified when the Pod-DTR transgene was present, 
and a 200-bp fragment when the Neph-VEGF-A165b transgene was 
present.
DT Toxicity
Precautions were taken to reduce the risk of DT toxicity to an-
imal handlers. All handlers had previously been immunised with 
DTP (diphtheria, tetanus and pertussis) vaccine. DT (Sigma Al-
drich) was prepared under a fume hood with full human protec-
tion, and special care was taken during administration of DT to 
animals. Upon completion of procedures, all surfaces were wiped 
down with 1 M NaOH to inactivate any DT that may have spilled. 
A previous study did not find any active DT in the urine or faeces 
from rats administered up to 500 ng/g bw DT [7], and therefore no 
special precautions were necessary here.
DT Experimental Protocol
Mice (3–5 per experimental groups) received a single intra-
peritoneal injection of DT diluted in PBS (or vehicle control) at 
6 weeks of age. Mice were culled by a schedule 1 method 14 days 
later. Metabolic cages were used to collect urine the day before DT 
administration, and then on days 1, 3, 5, 7, 10, and 14 post-DT ad-
ministration. Mice were inspected daily and if signs of illness de-
veloped, they were culled before the 14-day time point. Four doses 
of DT were used; 1, 5, 100, and 1,000 ng/g bw DT. No obvious 
gender differences were observed and therefore both male and fe-
male mice were included in the study.
Albumin and Creatinine Assays
Urine albumin measurements were assayed using a mouse-spe-
cific albumin ELISA Quantitation Set (Bethyl Laboratories). Urine 
creatinine was assayed using an Enzymatic Creatinine Assay 
(Thermo Scientific). Both assays were run with 3 technical repeats.
Oncometric Assay for Glomerular Water Permeability
Upon culling mice on day 14, kidneys were immediately re-
moved and placed in ice cold PBS; glomeruli were isolated from 
one pole using a set of sieves. Glomeruli were kept in 1% Bovine 
Serum Albumin (BSA; Sigma Aldrich) in mammalian Ringer so-
lution for no more than 4 h. During the isolation, the concentra-
tion of plasma proteins within the glomerular capillaries equili-
brates with the surrounding 1% BSA-Ringer solution. Single 
glomeruli were immobilised onto a micropipette tip using suc-
tion, within a micro-slide positioned under a microscope. The 
glomerulus is firstly perfused with 1% BSA, which is then switched 
to 8% BSA. The change in oncotic pressure results in fluid efflux 
from the glomerular capillaries, thereby changing the glomerular 
volume. The initial rate of volume change is used to estimate the 
glomerular water permeability normalised to glomerular vol-
ume. A more detailed methodology was previously published by 
Salmon et al. [20]. The glomerular water permeability (LpA/Vi) 
was measured in 4–6 glomeruli per mouse, from 3 to 5 mice per 
group.
Immunohistochemistry and Immunofluorescence
For immunohistochemistry studies, fresh renal cortex was 
fixed in 4% PFA and subsequently paraffin-embedded. Sections 
that were 5 μm thick were air-dried for 2 h prior to fixing with 4% 
PFA for 20 min. Antigen retrieval required heating slides in 0.01 M 
sodium citrate buffer (pH 6.0) for 12 min. Endogenous peroxidase 
activity was blocked with 3% (w/v) hydrogen peroxide and non-
specific IgG binding was then blocked with 1% BSA and 5% nor-
mal horse serum in PBS-Triton-X (0.05%) for 1 h. Primary anti-
body (human HB-EGF polyclonal Ab; R&D systems), or an IgG 
control, was applied to sections overnight. The next day, sections 
were incubated with a biotinylated secondary antibody (donkey 
anti-goat IgG; Vector Labs), followed by avidin-biotinylated en-
zyme complex buffer (Vector Labs), and then DAB substrate (Vec-
tor Labs) until sections changed colour from purple to brown. Sec-
tions were counter-stained with haematoxylin.
For immunofluorescence (IF) studies, kidney cortex was snap 
frozen in optimum cutting temperature embedding compound 
and sectioned using a cryostat. Sections, 5 μm thick, were then 
fixed with 4% PFA for 20 min. Sections were blocked with 3% BSA 
and 5% normal goat serum before incubating with primary anti-
body (anti-nephrin; Acris) overnight. The next morning, sections 
were incubated with an Alexa Fluor secondary antibody (goat an-
ti-guinea pig; Life Technologies). 
IHC and IF were performed on 3 sections of kidney cortex 
(technical repeats) per mouse, from 3 mice per group (biological 
repeats). Between 3 and 8 glomeruli were analysed from each tech-
nical repeat. Images were taken at 400× magnification.
Western Blotting
Protein was extracted from sieved glomeruli using NP-40 lysis 
buffer (Fisher Scientific) and subjected to polyacrylamide gel elec-
trophoresis (PAGE) on an SDS-polyacrylamide gel electrophoresis 
gel (BIO-RAD). After blotting, the membrane was probed with 
guinea pig polyclonal anti-nephrin (Acris) and rabbit polyclonal 
anti-podocin (Santa Cruz Biotechnology) overnight. The next day 
the bands were detected using fluorescent secondary antibodies 
(goat anti-guinea pig and goat anti-rabbit; Li-Cor Odyssey) and 
then imaged on a Li-Cor Odyssey. 
Protein was extracted from 3 mice per group, and 3 technical 
repeats were performed. Intensities were calculated using ImageJ. 
Transferase dUTP Nick End Labelling Assay
PFA-fixed sections of kidney cortex were subjected to a fluo-
rescent terminal deoxynucleotidyl transferase dUTP nick end la-
belling assay (Promega) to detect levels of DNA fragmentation re-
sulting from apoptotic signalling cascades in the glomerulus. A 
positive DNase-treated control was used. Experiments were per-
formed on sections from 3 mice per group, with 3 technical re-
peats. Between 3 and 5 glomeruli were analysed per repeat. Images 
were taken at 400× magnification.
Electron Microscopy
The ultra-structural phenotype was determined by fixing 
1 mm3 diced kidney cortex in 2.5% glutaraldehyde, post-fixing in 
1% osmium tetroxide, followed by embedding in Araldite (Agar 
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Scientific). Sections were cut at 50–100 nm and stained with 3% 
aqueous uranyl acetate and Reynolds’ lead citrate solution. Once 
imaged, measurements of the GFB were taken at random points 
using Adobe Photoshop. EM was carried out on the kidney cortex 
of 3 mice per group, 3 glomeruli per mouse.
Statistical Analysis
GraphPad Prism was used to conduct the statistical analysis. 
Values are expressed as mean ± SE of the mean (SEM). Fold change 
was calculated for uACR measurements by normalising the value 
for each individual animal at each time point to the baseline uACR 
for that particular animal, measured before experiments began. An 
unpaired Student t test was used for statistical analysis of datasets 
involving 2 groups. A one-way analysis of variance was used for 
statistical analysis of datasets with 3 or more groups, with a Bon-
ferroni post hoc test for comparison between pairs. Statistical sig-
nificance was set at p < 0.05.
Results
hDTR Is Expressed on the Podocytes of Pod-DTR Mice
Human DTR was detectable by immunohistochemis-
try in the glomeruli of Pod-DTR but not in WT mice 
(Fig. 1a). No hDTR was seen in the cells of the Bowman’s 
capsule. Therefore, we confirmed that the construct used 
to generate the Pod-DTR mouse strain (nephrin promot-
er-driven hDTR) resulted in the expression of hDTR on 
the podocytes at 6 weeks of age. Neph-VEGF-A165b mice 
were confirmed to express glomerular human VEGF-
A165b as previously described [17].
DT Increases Glomerular Water Permeability in 
Pod-DTR Glomeruli, Which Is Rescued by Podocyte 
Expression of VEGF-A165b
In one of our previous studies [14, 20], we have shown 
that measurement of glomerular permeability to water is 
an accurate and sensitive way to determine glomerular 
functional integrity. All mice were culled on day 14 post-
DT/PBS administration, and glomeruli were isolated for 
LpA/Vi measurements ex vivo. These were conducted on 
coded glomeruli by an observer blinded to the origin of 
the glomeruli studied. Pod-DTR mice treated with 1 ng/g 
bw DT had a significantly increased glomerular LpA/Vi 
14 days later (0.72 ± 0.14 mm Hg–1 min–1), compared to 
WT littermate controls (0.38 ± 0.045 mm Hg–1 min–1; p < 
0.05; Fig. 1b). This was also the case when Pod-DTR mice 
were treated with 5 and 1,000 ng/g DT (p < 0.05; Fig. 1c, 
d). However, when Pod-DTR mice also over-expressed 
VEGF-A165b in the podocytes (Pod-DTR X NephVEGF-
A165b), glomerular LpA/Vi was rescued back to values ob-
served in the DT-treated WT and Neph-VEGF-A165b 
controls groups (p < 0.01; Fig. 1b–d). Furthermore, there 
was no significant increase in glomerular LpA/Vi ob-
served between vehicle-treated Pod-DTR and DT-treated 
WT glomeruli (p < 0.05; Fig. 1d), indicating that the in-
creases in glomerular LpA/Vi observed in the Pod-DTR 
mice were due to the administration of DT.
We can therefore conclude that the Pod-DTR model 
does develop increased glomerular LpA/Vi in response to 
DT, although not in a dose-dependent manner. This rise 
in permeability is rescued when the podocytes over-ex-
press VEGF-A165b.
DT Administration Does Not Result in an 
Albuminuric Phenotype in Pod-DTR Mice
Data from previous characterization of this model sug-
gested a starting dose of 1 ng/g DT [10]. When this was 
injected intraperitoneally into WT, Pod-DTR, Neph-
VEGF-A165b and Pod-DTR X Neph-VEGF-A165b mice, 
no increases in uACR were observed in any of the groups 
on days 3, 5, 7, 10, and 14 post-DT administration (p = 
ns; Fig. 2a). Therefore, higher doses of DT were adminis-
tered; 5, 100, and 1,000 ng/g. None of the doses used re-
sulted in an increased uACR (p = ns; Fig. 2b–d). At the 
highest dose of DT, another group was added as an ad-
ditional control: Pod-DTR mice were administered ve-
hicle and not DT, as the mice may be sensitive to DT at 
such a high dose. However, no increases in uACR were 
observed in the DT-treated groups compared to vehicle-
treated controls (p = ns; Fig. 2d). Therefore, the Pod-DTR 
model did not develop albuminuria in response to a range 
of doses of DT.
DT Administration Did Not Result in Any Structural 
Abnormalities in Pod-DTR Mice
We examined the structure of Pod-DTR mouse glom-
eruli using light microscopy to determine whether treat-
ment with a single dose of DT measurably altered the glo-
merular structure. As shown in Figure 3ai and ii, treat-
ment of Pod-DTR and WT littermates with DT (1,000 
ng/g bodyweight) did not result in any detectable struc-
tural abnormalities, such as mesangial matrix expansion 
and glomerulosclerosis, 14 days later.
Furthermore, administration of DT did not result in 
any detectable changes to the glomerular ultra-structure, 
as assessed by EM (Fig. 3aiii, iv). There were no signifi-
cant changes in the GBM thickness (p = ns; Fig. 3bi), en-
dothelial fenestration number per μm length (p  = ns; 
Fig. 3bii), or in the podocyte slit width (p = ns; Fig. 3biii), 
14 days after administration of 1,000 ng/g bw DT to Pod-
DTR mice and WT littermates.
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DT Administration Did Not Result in Podocyte Loss 
in the Pod-DTR Mouse
A transferase dUTP nick end labelling assay did not 
detect any increases in cell apoptosis in Pod-DTR glom-
eruli 14 days after mice were treated DT (1,000 ng/g), 
when compared to DT-treated WT littermate controls 
(p = ns; Fig. 4). This therefore confirmed that DT admin-
istration in this model of Pod-DTR mice did not cause 
podocyte cell death, in contrast with the published litera-
ture on similar cell ablation models [6, 7].
DT Results in Altered Nephrin Staining and 
Expression in Pod-DTR Glomeruli, Which Is Partially 
Rescued by VEGF-A165b
Kidney sections were stained for nephrin, a podocyte 
marker, to assess podocyte and glomerular integrity. Pod-
DTR mice treated with 5 and 1,000 ng/g DT had a marked 
reduction in glomerular nephrin staining 14 days later in 
comparison to DT-treated WT and vehicle-treated Pod-
DTR controls (p < 0.05; Fig. 5a), expressed as a percentage 
glomerular area in Figure 5b. When Pod-DTR X Neph-
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Fig. 1. Podocyte-specific expression of human diphtheria toxin re-
ceptor (hDTR) results in an increased glomerular water permea-
bility, which is prevented in Pod-DTR X Neph-VEGF-A165b mice. 
a hDTR (HB-EGF) protein was detected in glomeruli of transgen-
ic Pod-DTR (aii) but not wild-type (WT) mice (ai). b–d Glomeru-
lar water permeability (LpA/Vi) was elevated 14 days after a single 
dose of 1, 5, and 1,000 ng/g bw DT in Pod-DTR mice compared to 
DT-treated WT and untreated Pod-DTR controls (* p < 0.05). In-
creased LpA/Vi was significantly rescued in Pod-DTR X Neph-
VEGF-A165b mice at all doses of DT (* p < 0.05, ** p < 0.01; n = 3–5 
mice, 13–24 glomeruli; 1 way analysis of variance [ANOVA] with 
Bonferroni comparison between pairs was used to analyse the 
data).
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VEGF-A165b mice received the same dose of DT, the per-
centage glomerular area stained with nephrin was signif-
icantly increased, in comparison with Pod-DTR mice, to-
wards that measured in DT-treated WT mice. Therefore, 
over-expression of VEGF-A165b in the podocytes of Pod-
DTR mice prevented the DT-induced reduction in neph-
rin staining seen in the Pod-DTR mice at both doses (p < 
0.05; Fig. 5a, b).
The renal cortex protein expression of 2 key podocyte 
markers, nephrin and podocin, was evaluated by WB in 
all 4 groups of mice treated with 5 and 1,000 ng/g DT. 
There was a significant reduction of nephrin in Pod-DTR 
mice and rescue of the expression in Pod-DTR X Neph-
VEGF-A165b mice, correlating with the immunostaining 
(p < 0.05; Fig. 5c). There was no evidence of a consistent 
reduction in podocin proteins in Pod-DTR mice in com-
parison to DT-treated WT controls (p = ns; Fig. 5c).
Discussion
The Pod-DTR mouse was confirmed to express hDTR 
within the glomeruli and was successfully crossed with 
the Neph-VEGF-A165b mouse to generate a double trans-
genic that expressed both hDTR and human VEGF-A165b 
on/within the podocyte. Pod-DTR mice treated with 
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Fig. 2. Pod-DTR mice do not become albuminuric with varying 
doses of DT. The urinary albumin: creatinine ratio (uACR) was 
measured at various time points after DT administration and then 
normalised to baseline uACR in the 4 groups of mice; WT, Pod-
DTR, Neph-VEGF-A165b, and Pod-DTR X Neph-VEGF-A165b. 
No increases in uACR were observed in Pod-DTR mice at any dose 
of DT; 1 ng (a), 5 ng (b), 100 ng (c) and 1,000 ng/g bw (d), up to 
14 weeks post DT treatment, when compared to DT-treated WT, 
Neph-VEGF-A165b, Pod-DTR X Neph-VEGF-A165b and untreat-
ed Pod-DTR littermate controls (n = 3–5 mice, p = ns; 1 way anal-
ysis of variance [ANOVA] with Bonferroni comparison between 
pairs).
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varying doses of DT did not become albuminuric after 
2 weeks, or develop any detectable glomerular structural/
ultra-structural abnormalities. However, there was evi-
dence of impaired podocyte function as DT did result in 
a significant increase in glomerular water permeability 
(LpA/Vi) in Pod-DTR mice, although not in a dose-de-
pendent manner. This phenotype was accompanied by a 
40–50% reduction in nephrin staining intensity, as as-
sessed by IF and Western blot, in Pod-DTR mice, indica-
tive of potential podocyte injury possibly related to the 
rearrangement of the proteins of the slit diaphragm, spe-
cifically nephrin. The total expression of podocyte-specif-
ic protein podocin remained unchanged in DT-treated 
Pod-DTR glomeruli, and no increase in podocyte apop-
tosis was observed, leading us to conclude that DT is not 
resulting in podocyte ablation. Over-expression of hu-
man VEGF-A165b within the podocytes of Pod-DTR mice 
resulted in the prevention of the increased glomerular 
LpA/Vi and the alterations in nephrin staining, indicating 
that VEGF-A165b has a cyto-protective effect on the podo-
cytes in response to DT. 
This colony of Pod-DTR mice were previously charac-
terised and a single dose of 1 ng/g bw DT was stated as the 
optimal dose to induce transient albuminuria 7–14 days 
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Fig. 3. Pod-DTR mice did not develop any glomerular structural 
abnormalities. a Haematoxylin and Eosin (H&E) staining did not 
detect any glomerular structural abnormalities in Pod-DTR mice 
treated with up to 1,000 ng/g bw DT after 14 days compared with 
DT-treated WT controls (n = 3 mice, 10–12 glomeruli, images tak-
en at 400× magnification). b Electron microscopy of the GFB in 
Pod-DTR mice treated with 1,000 ng/g bodyweight DT after 14 
days did not show any changes in GBM width (bi), endothelial fe-
nestrae number (bii) or podocyte slit width (biii), in comparison 
to DT-treated WT controls (n = 3 mice, 9 glomeruli, p = ns, un-
paired t test).
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later [10]. Studies using similar podocyte expressing 
hDTR models found an optimal dose of 25 ng/g bw DT 
was appropriate to induce transient proteinuria 7 days 
later [6, 7]. Within the current study, we found that even 
with a dose of 1,000 ng/g bw DT, no albuminuria was ob-
served within the first 2 weeks post-administration. Gen-
erally, few mouse strains develop high levels of protein-
uria with it being widely accepted that C57BL/6 mice are 
very resistant to high levels of proteinuria and renal dis-
ease [21]. However, the problem lies that many geneti-
cally altered mice are currently on a C57BL/6 background, 
including the mice used within this study. 
This is the first study to measure the glomerular LpA/
Vi in a podocyte-specific injury model of glomerular dis-
ease. This accurate and reproducible assay, although not 
widely used due to its technical difficulties, is a robust 
method of measuring the isolated glomerular ultra-fil-
tration coefficient independent of circulating and hae-
modynamic factors [20, 22]. Recent studies have corre-
lated an increased glomerular LpA/Vi to albuminuria 
[15], which has been found to be a more sensitive assay 
to changes in GFB function than measuring the uACR 
[14]. Although the Pod-DTR mice do not become albu-
minuric in response to DT, there is a significant increase 
in glomerular LpA/Vi at all doses of DT administered. 
Therefore, our study confirms that this oncometric glo-
merular permeability assay is a more sensitive technique 
for detecting subtle changes in glomerular function. At 
this stage, it appeared reasonable to assume that DT was 
causing a low amount of podocyte ablation in the Pod-
DTR mice to account for this phenotype. However, 
when we measured cell apoptosis within the glomerulus 
it became evident that DT-treated Pod-DTR mice had 
no increase in podocyte apoptosis. This was further sup-
ported by the lack of reduction in expression of podo-
cyte-specific proteins podocin, in DT-treated Pod-DTR 
glomeruli, and no detectable podocyte structural abnor-
malities. When looking at the arrangement of nephrin 
staining within the glomeruli of Pod-DTR mice, there 
did appear to be changes in the intensity of nephrin ex-
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Fig. 4. Pod-DTR mice treated with DT did not exhibit podocyte 
loss. a TUNEL staining showed now increased cell apoptosis in 
glomeruli from Pod-DTR mice 14 days after treatment with 1,000 
ng/g bw DT, in comparison to DT-treated WT littermate controls 
(summarised in b). DNase treatment served as a positive control 
(n = 3 mice, p = ns, unpaired t test).
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pression; reducing in response to DT in Pod-DTR glom-
eruli, and a slight reduction in the expression of the pro-
tein by Western blot at 5 ng/g but not 1,000 ng/g. This 
suggests a rearrangement of nephrin within the podo-
cyte in response to DT, resulting in the dysfunction of 
the slit diaphragm and thus increased glomerular water 
permeability phenotype. Indeed, the interaction be-
tween nephrin and Neph1 in the slit diaphragm has pre-
viously been reported to alter glomerular permeability 
[23].
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Despite only observing a mild phenotype in this mod-
el, over-expression of VEGF-A165b in the podocytes of the 
Pod-DTR mice did result in the prevention of the in-
creased glomerular LpA/Vi and proposed rearrangement 
of nephrin. This correlates with previous studies where 
VEGF-A165b over-expression/treatment was found to re-
duce glomerular LpA/Vi, both in vivo and ex vivo, in 
healthy murine and human glomeruli [14, 17], and in cas-
es of murine and human glomerular disease [14, 15]. Fur-
thermore, VEGF-A165b exhibits cyto-protective proper-
ties when applied to podocytes in culture [24], and thus 
appears to be protective against detrimental alterations to 
nephrin induced by DT in the Pod-DTR model of glo-
merular disease. We speculate that the mechanism of 
VEGF-A165b in reducing the glomerular LpA/Vi may be 
due to its previously reported effects on reducing the glo-
merular endothelial fenestration density, thus reducing 
permeability [17]. Furthermore, the treatment of condi-
tionally immortalised GEnCs with VEGF-A165b has been 
reported to reduce the phosphorylation of VEGFR2, 
which in turn could decrease the permeability of the GFB 
[25]. On the other hand, podocyte-specific over-expres-
sion of the pro-permeability isoform, VEGF-A164, has 
been reported to result in glomerular dysfunction includ-
ing increased glomerular LpA/Vi, which could be rescued 
by the constitutive over-expression of VEGF-A165b [14], 
and a collapsing nephropathy phenotype [26]. It appears 
that while upregulation of the pro-permeability VEGF-
A164 isoform is detrimental to glomerular function, up-
regulation of the anti-permeability VEGF-A165b isoform 
is beneficial to glomerular function.
DT did not induce any ultra-structural abnormalities 
in the Pod-DTR mice in our study. There is substantial 
evidence to suggest that structural defects in the GFB are 
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Fig. 5. Nephrin staining and expression are altered in Pod-DTR 
glomeruli after DT administration and this is rescued by podocyte 
expression of VEGF-A165b. a Kidney sections from WT, Pod-DTR, 
Neph-VEGF-A165b and Pod-DTR X Neph-VEGF-A165b treated 
with 5 and 1,000 ng/g bw DT, and untreated Pod-DTR+/– mice, 
were stained for nephrin as an indicator of podocyte function. 
Nephrin staining is expressed as a percentage of the total glomeru-
lar area (b). DT resulted in a decrease in glomerular nephrin stain-
ing in Pod-DTR mice (** p < 0.01), which is rescued at both doses 
by podocyte expression of VEGF-A165b (** p < 0.01). DT-treated 
Neph-VEGF-A165b and untreated Pod-DTR mice showed no dif-
ference to DT-treated WT controls at either concentration of DT. 
Images taken at 400× magnification (n = 3 mice, 1 way analysis of 
variance [ANOVA] with Bonferroni comparison between pairs 
was used to analyse the data). c The protein expression of nephrin, 
but not podocin, within the glomerular cortex was decreased in 
Pod-DTR mice after treatment with 5 but not 1,000 ng/g bw DT, 
in comparison to WT, Neph-VEGF-A165b and Pod-DTR X Neph-
VEGF-A165b mice (n = 3 mice, * p < 0.05, ** p < 0.01, *** p < 0.001, 
1 way ANOVA with Bonferroni comparison between pairs).
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largely a result of albuminuria in specific disease condi-
tions [27], which could explain why we do not see any 
structural abnormalities in our model. 
The potential limitations to the present study are that 
we only see a mild phenotype of glomerular disease in the 
Pod-DTR mice. Therefore, we are not able to see the full 
therapeutic potential of VEGF-A165b in the glomerulus, 
as reported in the previous studies mentioned. In addi-
tion, the number of mice per group was relatively low; 
however, we overcame this limitation by using multiple 
doses of DT, and thus had multiple groups of mice being 
treated with DT. Furthermore, the genetic background of 
the Pod-DTR mouse used in this study was not ideal to 
study glomerular disease.
In conclusion, the lower dose Pod-DTR model used 
in this study is a mild model of glomerular disease, with 
no measurable albuminuria apparent within the first 
weeks after administration of DT and no detectable 
structural/ultra-structural defects. However, an in-
creased glomerular water permeability correlated to a 
change in nephrin within the podocytes was observed in 
this model. The resultant phenotype disagrees with the 
severe podocyte ablation reported in published models, 
which could be due to a number of factors including a 
development of insensitivity to DT, different animal 
housing conditions or reduced expression of hDTR over 
time. Despite the drawbacks of this model, we can con-
clude that the mild phenotype of glomerular disease in 
Pod-DTR mice was successfully prevented by constitu-
tive over-expression of cyto-protective VEGF-A165b 
within the podocytes, underlying the importance and 
therapeutic potential of the VEGF-A165b splice variant in 
glomerular disease.
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